TY - JOUR
T1 - Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network
AU - Ferrajolo, Carmen
AU - Coloma, Preciosa M.
AU - Verhamme, Katia M.C.
AU - Schuemie, Martijn J.
AU - De Bie, Sandra
AU - Gini, Rosa
AU - Herings, Ron
AU - Mazzaglia, Giampiero
AU - Picelli, Gino
AU - Giaquinto, Carlo
AU - Scotti, Lorenza
AU - Avillach, Paul
AU - Pedersen, Lars
AU - Rossi, Francesco
AU - Capuano, Annalisa
AU - Van Der Lei, Johan
AU - Trifiro, Gianluca
AU - Sturkenboom, Miriam C.J.M.
N1 - Funding Information:
Conflicts of interest Martijn J. Schuemie has become an employee of Janssen R&D since completing this research and has received a grant from the Foundation for the National Institutes of Health (FNIH). Katia M.C. Verhamme received unconditional research grants from Pfizer, Boehringer-Ingelheim, Novartis and Yamanouchi. None of these are related to the content of this research. Carmen Ferrajolo, Preciosa M. Coloma, Sandra de Bie, Rosa Gini, Giampiero Mazzaglia, Gino Picelli, Carlo Giaquinto, Lorenza Scotti, Paul Avillach, Lars Pedersen, Francesco Rossi, Annalisa Capuano, Johan van der Lei, Ron Herings, Miriam C.J.M. Sturkenboom and Gianluca Trifiró declare that they have no conflicts of interest directly relevant to the content of this study.
Funding Information:
Acknowledgments This research has been funded by the European Commission Seventh Framework Programme (FP7/2007-2013) under grant no. 215847—the EU-ADR Project. The funding agency had no role in the design and conduct of the study, the collection and management of data, the analysis or interpretation of the data or preparation, review, or approval of the manuscript.
PY - 2014/2
Y1 - 2014/2
N2 - Background Data mining in spontaneous reporting databases has shown that drug-induced liver injury is infrequently reported in children. Objectives Our objectives were to (i) identify drugs potentially associated with acute liver injury (ALI) in children and adolescents using electronic healthcare record (EHR) data; and (ii) to evaluate the significance and novelty of these associations. Methods We identified potential cases of ALI during exposure to any prescribed/dispensed drug for individuals <18 years old from the EU-ADR network, which includes seven databases from three countries, covering the years 1996-2010. Several new methods for signal detection were applied to identify all statistically significant associations between drugs and ALI. A drug was considered statistically significantly associated with ALI, using all other time as a reference category, if the 95 % CI lower band of the relative risk was >1 and in the presence of at least three exposed cases of ALI. Potentially new signals were distinguished from already known associations concerning ALI (whether in adults and/or in the paediatric population) through manual review of published literature and drug product labels. Results The study population comprised 4,838,146 individuals aged <18 years, who contributed an overall 25,575,132 person-years of follow-up. Within this population, we identified 1,015 potential cases of ALI. Overall, 20 positive drug-ALI associations were detected. The associations between ALI and domperidone, flunisolide and human insulin were considered as potentially new signals. Citalopram and cetirizine have been previously described as hepatotoxic in adults but not in children, while all remaining associations were already known in both adults and children. Conclusions Data mining of multiple EHR databases for signal detection confirmed known associations between ALI and several drugs, and identified some potentially new signals in children that require further investigation through formal epidemiologic studies. This study shows that EHRs may complement traditional spontaneous reporting systems for signal detection and strengthening.
AB - Background Data mining in spontaneous reporting databases has shown that drug-induced liver injury is infrequently reported in children. Objectives Our objectives were to (i) identify drugs potentially associated with acute liver injury (ALI) in children and adolescents using electronic healthcare record (EHR) data; and (ii) to evaluate the significance and novelty of these associations. Methods We identified potential cases of ALI during exposure to any prescribed/dispensed drug for individuals <18 years old from the EU-ADR network, which includes seven databases from three countries, covering the years 1996-2010. Several new methods for signal detection were applied to identify all statistically significant associations between drugs and ALI. A drug was considered statistically significantly associated with ALI, using all other time as a reference category, if the 95 % CI lower band of the relative risk was >1 and in the presence of at least three exposed cases of ALI. Potentially new signals were distinguished from already known associations concerning ALI (whether in adults and/or in the paediatric population) through manual review of published literature and drug product labels. Results The study population comprised 4,838,146 individuals aged <18 years, who contributed an overall 25,575,132 person-years of follow-up. Within this population, we identified 1,015 potential cases of ALI. Overall, 20 positive drug-ALI associations were detected. The associations between ALI and domperidone, flunisolide and human insulin were considered as potentially new signals. Citalopram and cetirizine have been previously described as hepatotoxic in adults but not in children, while all remaining associations were already known in both adults and children. Conclusions Data mining of multiple EHR databases for signal detection confirmed known associations between ALI and several drugs, and identified some potentially new signals in children that require further investigation through formal epidemiologic studies. This study shows that EHRs may complement traditional spontaneous reporting systems for signal detection and strengthening.
UR - http://www.scopus.com/inward/record.url?scp=84897944112&partnerID=8YFLogxK
U2 - 10.1007/s40264-013-0132-9
DO - 10.1007/s40264-013-0132-9
M3 - Article
SN - 0114-5916
VL - 37
SP - 99
EP - 108
JO - Drug Safety
JF - Drug Safety
IS - 2
ER -